Cls12311 Low, Cls12311 Medium, Cls12311 High, Uncoupled Rbcs
Relapsing-Remitting Multiple Sclerosis (Rrms)
Phase I
Active Not Recruiting
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
May 06, 2024
―
Imx-110 Combined With Tislelizumab
Advanced Solid Tumor
Phase I/II
Unknown
Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Jan 04, 2023
―
Ribociclib, Everolimus, Alpelisib, Palazestrant
Breast Cancer, Metastatic Breast Cancer, Her2-Negative Breast Cancer, Er-Positive Breast Cancer, Locally Advanced Breast Cancer
Phase I
Active Not Recruiting
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, or Everolimus in ER+, HER2- Breast Cancer
Aug 16, 2022
―
Fulvestrant, Alpelisib, Tucatinib
Her2-Positive Metastatic Breast Cancer
Phase I/II
Recruiting
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Dec 27, 2021
―
Ketamine
Healthy
Early Phase I
Completed
Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers
May 28, 2021
―
Mrtx849, Tno155
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Phase I
Completed
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Mar 30, 2020
―
Amg334, Oral Prophylactic
Episodic Migraine
Phase IV
Completed
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
Apr 23, 2019
―
Erenumab
Migraine
Phase IV
Terminated
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
Apr 10, 2019
―
Daratumumab, Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Pembrolizumab, Capecitabine, Temozolomide, Pemetrexed, Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Rucaparib, Regorafinib, Enzalutamide, Sunitinib
Cancer
Phase II
Recruiting
Pan Tumor Rollover Study
Apr 01, 2019
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3
Migraine
Phase III
Active Not Recruiting
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Jan 29, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Novartis AG (NOT) have in its pipeline
NOT is currently developing the following drugs: Cls12311 Low, Cls12311 Medium, Cls12311 High, Uncoupled Rbcs, Imx-110 Combined With Tislelizumab, Ribociclib, Everolimus, Alpelisib, Palazestrant. These drug candidates are in various stages of clinical development as the company works toward FDA approval.